StockPriceToday
Editas Medicine Inc. (EDIT)
About Editas Medicine Inc.
Editas Medicine Inc. was founded in 2013 by pioneers in CRISPR genome editing technology and has established itself as one of the leading companies developing therapeutic applications of CRISPR-Cas9 and other genome editing platforms. The company has built comprehensive capabilities in genome editing, including proprietary technologies and manufacturing processes that enable precise genetic modifications to treat serious genetic diseases. Editas has advanced multiple therapeutic programs into clinical development, focusing on diseases of the eye, blood, and other organs where genome editing can provide transformative treatment options. Biotechnology sector dynamics, gene therapy development, and clinical trial results significantly influence EDIT stock price as investors evaluate the company's potential in the pioneering genome editing therapeutics market.
The company is led by CEO Gilmore O'Neill, who has extensive experience in biotechnology development and has guided Editas through clinical advancement and strategic partnerships. The management team includes experienced professionals in gene therapy, clinical development, and manufacturing who understand the unique challenges and opportunities in genome editing medicine. Their strategic focus on platform technology development, clinical execution, and manufacturing capabilities has positioned Editas to advance genome editing therapeutics from laboratory to patients. These leadership capabilities and strategic decisions directly impact investor confidence and EDIT stock price as the company advances its clinical programs and seeks to establish genome editing as a transformative therapeutic modality.
Editas Medicine operates as a clinical-stage biotechnology company, focusing resources on advancing genome editing therapeutic candidates through clinical trials while building platform technologies and manufacturing capabilities that support genomic medicine development. The company generates limited revenue through research collaborations and licensing agreements while investing substantially in clinical development and platform advancement. With multiple therapeutic candidates targeting significant market opportunities in genetic diseases and pioneering genome editing technology, Editas represents both substantial growth potential and the inherent risks of developing novel therapeutic modalities. For investors, understanding gene therapy market dynamics, clinical development challenges, and the competitive landscape in genome editing is important when evaluating the company's prospects and factors affecting stock price performance in the biotechnology sector.
EDIT Stock 12 Month Chart
Latest News for EDIT
Editas Medicine stock is due to report third-quarter results on November 9. EDIT-401 remains the key clinical focus ahead of human dosing. Editas Medicine is scheduled to report third-quarter results ...
Second-quarter revenue was USD 11.89 million versus USD 2.85 million expected. Editas Medicine stock costs EUR 2.34 on October 20, 2026 at 8:20 p.m. CEST. Wells Fargo raised its Editas Medicine target ...
CRISPR Therapeutics holds a first-mover advantage as a commercial-stage leader with an approved gene-editing therapy on the market. Editas Medicine is strategically pivoting toward in vivo gene ...
Other Popular Stocks
Taboola.com Ltd. warrants (TBLAW) provide the right to purchase TBLA common stock at a predetermined price, offering leveraged exposure to the content discovery and...
Kingsoft Cloud Holdings Limited (KC) is a cloud services company providing infrastructure, platform, and software solutions primarily in China and other Asian markets.
Dawson Geophysical Company (DWSN) is a leading provider of onshore seismic data acquisition services for the oil and gas industry in the continental United...